GlobeNewswire by notified

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target


PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

  • Klebsiella pneumoniae is responsible for severeinfections and stands out for its high resistance to antibiotics

  • PHAXIAM'santi-Klebsiella pneumoniae phages to enter pre-clinical development to assess their efficacy in lung, blood and urinary tract infections, in addition to the three major targets already developed (S. aureus, P. aeruginosa, E.coli)

Lyon (France) and Cambridge (MA, US), September 19, 2023 07:00 a.m. CEST – PHAXIAMTherapeutics (Nasdaq & Euronext: FR0011471135), today announces the launch of a new preclinical development targeting a strong antimicrobial-resistant bacteria, Klebsiella pneumonia.

Klebsiella pneumoniae (K. pneumoniae) causes a wide range of infections, including pneumonia, urinary tract infections, bacteremia and liver abscesses, and mainly infects immunocompromised people. However, the emergence and spread of hypervirulent and multi-resistant strains of this bacterium have recently extended its potential targets to people with no health problems.

In Western countries, we estimate that between 3% and 5% of pneumonias are linked to an infection caused by K. pneumoniae. Worldwide, K. pneumoniae is responsible for 11.8% of hospital-acquired pneumonia. In high-risk patients (alcoholics and septicemics), the mortality rate associated with this kind of infection is between 50 and 100%1. The incidence of K. pneumoniae resistances is evaluated between 90-100,000 patients in the US and EU52, mainly in Urinary Tract infections and Respiratory Tract infections.

Recent studies in Europe and the United States3,4 also revealed the existence of K. pneumoniae strains with an exceptionally high level of antimicrobial resistance, making them even more difficult to treat. The results of these studies demonstrated a worrying trend among the samples collected, which may even be resistant to enzyme-inhibiting antibiotics that have recently been developed but have not yet been marketed. This level of antimicrobial resistance in K. pneumoniae strains had never been observed before.

Selected phages will be evaluated on a wide range of infections in which PHAXIAM already benefits from considerable expertise, such as lung, blood and urinary tract infections. This will enable the Company to capitalize on preclinical models validated with its three historical phage families, mutualize certain developments within the same indication and accelerate the progression to clinical phases.

Thibaut du Fayet, Chief Executive Officerof PHAXIAM Therapeutics, stated: With the launch of this new program, PHAXIAM Therapeutics deploys its strategy in line with the plan presented during the merger, and reaffirms its position at the forefront of the fight against antimicrobial resistance. K. pneumoniae bacteria represents a new target with a high medical need, affecting a large population worldwide, and for which antibiotics offer only a limited therapeutic solution. Our anti-Klebsiella phages will thus complement analready extended phage portfolio for the clinical indicationswe are targeting,and reinforce our ability to efficiently address a broad spectrum of resistant bacterial infections.

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAXIAM is listed on the Nasdaq Global Select Market in the United States (ticker: PHXM – to be modified to a new symbol) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit


Eric Soyer
Deputy CEO, COO & CFO
+33 4 78 74 44 38

Mathilde Bohin / Dušan Orešanský
Investor Relations
Arthur Rouillé
Media Relations
+33 1 44 71 94 94

1 John V. Ashurst; Adam Dawson ET AL., 2022.
2 Five main European countries: France, Germany, UK, Spain & Italy
3Highly multidrug-resistant Gram-negative bacterial infections in war victims in Ukraine, 2022; The Lancet Infectious Diseases
4NIH investigates multidrug-resistant bacterium emerging in community settings; National Institutes of Health (NIH)


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Technicolor Creative Studios: Business Update and First Half 2023 Financial Results2.10.2023 21:55:38 CEST | Press release

CORPORATE PRESS RELEASE Technicolor Creative StudiosBusiness Update and First Half 2023Financial Results PARIS (FRANCE), OCTOBER 2,2023 – Technicolor Creative Studios (Euronext Paris: TCHCS) (the “Company”) today provided business update and announced its first half 2023 financial results1. Acceleration of the transformation plan to drive the recovery of the business Impact of strikes in Hollywood andunfavourable macroeconomic environment led to reduction of activity withlower financial and operational performancefor thefirst half 2023Renewed confidence from majority shareholders and lenders with:An additional €30 million of new money injection to address liquidity needs A proposed tender offer (“offre publique d’achat simplifiée”)at a price of 1,63 euro per share, dividends included,to beinitiated by a large majority of shareholders and lenders (holding 94,82% of the capital) acting in concert in view of proceeding to a mandatory squeeze outto achieve delisting of Technicolor Creative

Meltwater launches new mChampion program in the Meltwater Customer Community2.10.2023 21:39:09 CEST | Press release

SAN FRANCISCO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Meltwater, a leading global provider of social, media and consumer intelligence, today announces the launch of its new mChampions Community Rewards Program to enhance customer experience and provide career elevation and networking opportunities, in the Meltwater Customer Community. Meltwater’s Customer Community, mCommunity, is an online, self-service community for Meltwater customers to share knowledge, challenges, best practices and experiences to build skills and advance their careers in PR, Communications and Marketing. With over 7,000 members and several community-led discussion boards and groups established, mCommunity has created an environment where users can collaborate and succeed together. Today, through Meltwater’s customer-centric approach and commitment to fostering knowledge sharing through mCommunity, Meltwater has taken a significant leap forward with the introduction of the mChampions program – a rewards program exclusi

SKEL fjárfestingafélag hf.: Buy-back programme week 392.10.2023 20:04:24 CEST | Press release

In week 39 2023, SKEL fjárfestingafélag hf. purchased in total 7,350,000 own shares for total amount of 96,345,000 ISK as follows: DateTimePurchased sharesPricePurchase priceTotal own shares25.9.202309:35:00 500,000 13.30 6,650,000 27,118,518 25.9.202310:25:00 500,000 13.25 6,625,000 27,618,518 25.9.202314:49:00 500,000 13.30 6,650,000 28,118,518 25.9.202314:50:00 500,000 13.30 6.650.000 28,618,518 26.9.202309:53:00 500,000 13.40 6.700.000 29,118,518 26.9.202310:08:00 500,000 13.40 6.700.000 29,618,518 26.9.202312:49:00 500,000 13.25 6.625.000 30,118,518 26.9.202314:14:00 500,000 13.20 6.600.000 30,618,518 27.9.202310:04:00 500,000 12.90 6.450.000 31,118,518 27.9.202312:54:00 500,000 12.85 6.425.000 31,618,518 27.9.202314:21:00 450,000 12.85 5.782.500 32,068,518 27.9.202315:29:00 450,000 12.85 5.782.500 32,518,518 28.9.202310:01:00 450,000 12.90 5.805.000 32,968,518 28.9.202315:06:00 1,000,000 12.90 12.900.000 33,968,518 7,350,00096,345,00033,968,518 The execution of the buy-back progr

Nokia Corporation: Repurchase of own shares on 02.10.20232.10.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 2 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.10.2023 Espoo, Finland – On 2 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL341,8703.53CEUX35,2183.53AQEU1,5003.53TQEX22,4123.56Total401,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023